TLR9 and neoplasm: A dual-action lipid nanoparticle (dual-LNP) that co-delivered VISTA-specific siRNA and a TLR9 agonist (CpG) showed superior anti-tumor efficacy, effectively silencing VISTA expression and enhancing cytotoxic T cell responses in melanoma and colon carcinoma models [304].